deltatrials
Completed PHASE2 INTERVENTIONAL 7-arm NCT00231413

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)

Sponsor: GlaxoSmithKline

Conditions Infections, Papillomavirus
Interventions HPV 16/18 L1 AS04 HPV-16/18/31/45 L1 AS04 Formulation 1 HPV-16/18/31/45 L1 AS04 Formulation 2 HPV-16/18/31/45 L1 AS04 Formulation 3 HPV-16/18/31/45 L1 AS04 Formulation 4 HPV-16/18/31/45 L1 AS04 Formulation 5 HPV-16/18/31/45 L1 AS04 Formulation 6
Updated 7 times since 2017 Last updated: Nov 25, 2019 Started: Mar 4, 2005 Primary completion: Mar 27, 2006 Completion: Mar 27, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00231413, this PHASE2 trial focuses on Infections, Papillomavirus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2020 · 19 months · monthly snapshotCompleted~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2020 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations